Esperion confirms FDA acceptance of two NDAs for regulatory review
Category: #health  By Mateen Dalal  Date: 2019-05-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Esperion confirms FDA acceptance of two NDAs for regulatory review

The NDAs are for oral therapies developed as medication for patients with raised LDL-C who require additional LDL-C lowering

Esperion has recently announced that the U.S. Food and Drug Administration has officially accepted both bempedoic acid & bempedoic acid/ezetimibe combination tablet New Drug Applications for filing as well as regulatory review.

Apparently, the bempedoic acid and bempedoic acid-ezetimibe combination tablet have been developed as affordable, suitable, once-daily, complementary, oral therapies for the medication of patients with raised low-density lipoprotein cholesterol or LDL-C who require additional lowering of LDL-C in spite of using presently accessible therapies.

Sources mentioned that the Prescription Drug User Fee Act (PDUFA) goal date is set for 21 February 2020 for the completion of the NDA review of bempedoic acid. The PDUFA goal date for completing the NDA review of bempedoic acid/ezetimibe combination tablet is set for 26 February 2020.

Chief Executive Officer and President of Esperion, Tim M. Mayleben, confirmed that both New Drug Applications have been accepted for filing by the US FDA.

Mayleben said that the acceptances for regulatory review of these therapies confirm the superior-quality submissions and outstanding effort of the company’s Lipid Management Team, bringing the acid-based therapies of oral bempedoic further close to the patients and physicians who will benefit from them.

Seemingly, the worldwide LDL-C Phase 3 Lowering Program of Esperion has been undertaken to support EMA and FDA Submissions. The company completed its worldwide, pivotal, Phase 3 clinical development program as well as unveiled positive cumulative results previous year in October.

The program evaluated the consistency, safety and tolerability, complementary LDL-C-lowering efficiency of bempedoic acid/ezetimibe combination tablet and bempedoic acid in patients with ASCVD or who are at high risk for ASCVD.

Sources further mentioned that bempedoic acid/ezetimibe combination tablet and bempedoic acid are new medication applications are under supervisory review by FDA. The marketing authorization applications for these product applicants are also under regulatory review by European Medicines Agency.

Source Credit: https://www.nasdaq.com/press-release/esperion-announces-us-fda-acceptance-of-new-drug-applications-ndas-for-both-bempedoic-acid-and-the-20190505-00013

https://investor.esperion.com/news-releases/news-release-details/esperion-announces-us-fda-acceptance-new-drug-applications-ndas

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Saudi Arabia aims for net-zero carbon emissions by the year 2060
Saudi Arabia aims for net-zero carbon emissions by the year 2060
By Mateen Dalal

Global oil producer, Saudi Arabia has recently stated that it intends to reach zero greenhouse gas emission levels by 2060, thereby joining the bandwagon with other 100 countries towards limiting the impact of climate change. Although the kingdom pl...

Abbott unites with Real Madrid to aid child welfare worldwide
Abbott unites with Real Madrid to aid child welfare worldwide
By Mateen Dalal

Abbott’s partnership with Real Madrid will cater to children’s education, social welfare, sports activities in around 80 countries It will also provide health and nutritional assistance to Academy teams and product development and inn...

TotalEnergies commences its UK Offshore Wind Hub in Scotland
TotalEnergies commences its UK Offshore Wind Hub in Scotland
By Mateen Dalal

French oil and gas major, TotalEnergies SE has inaugurated its UK Offshore Wind Hub in Scotland which will be part of the company's existing offshore operations center in Aberdeen and allow employees to shift from oil and gas to offshore win...